壮腰健肾丸引起过敏反应1例报道

1病例报告患者,女,59岁,2003年9月1日19时因腰痛服用壮腰健肾丸1粒(江西侨业药业有限公司生产,剂量:5.6g/丸,批号:030112),服药约20min后,开始出现皮肤搔痒、唇舌肿大、头晕、呕吐、眼睛视物不清、呼吸困难等症状,后患者昏迷,即送入上犹县中医院治疗。入院时体格检查:患者呼吸急促、双眼睑充血、两肺呼吸音粗、未闻及干湿罗音、心率增快、四肢皮肤可见皮疹。T36.5℃、P120次/min、BP70/50kPa,初步诊断:过敏反应。给予静脉滴注5%葡萄糖注射液加维生素C、ATP、辅酶A、欣维、克林霉素静滴、扑尔敏10mg肌注、地塞米松10mg肌注,连续治疗3d,患…     

壳聚糖预防兔眼眶手术术后组织粘连

目的了解壳聚糖对预防眼眶组织粘连的效果,为临床应用提供实验依据。方法家兔15只,采用自身对照方法,右眼为实验组,左眼为对照组,分别制作眶壁缺损模型,缺损区实验组应用2%壳聚糖凝胶,对照组应用平衡盐溶液。术后4周对术区行大体观察及组织学光镜观察。结果临床观察各组兔眼未见明显异常体征。术后4周,大体观察实验组术区组织粘连程度较对照组明显为轻,组织学切片光镜观察见实验组骨膜与瘢痕组织之间粘连较轻,瘢痕组织增生较少,成纤维细胞数目较少,体积小,排列整齐,较疏松,成熟细胞较少;对照组骨膜与瘢痕组织粘连重,瘢痕组织增生多,大量成纤维细胞,排列紊乱、密集,多数呈梭形,趋于成熟。结论壳聚糖能减轻眼眶术后组织粘连,无明显不良反应,可进一步应用于眼科临床,减少眼眶手术术后并发症。     

LASIK后弥漫性板层角膜炎的临床分析

Objective To study the causes,clinical features and prevention measures of diffuse lamel-lar keratitis (DLK)after LASIK. Methods Eleven patients ( 17 eyes) with DLK after LASIK among 199 pa-floats (398 eyes) from March 2007 to December 2007 were selected as observation group,and after the strict checks on operating room environment,pressure sterilizer,surgical instrument disinfection,preoperative con-junctival sac clean and corneal epithelium protection,5 patients (7 eyes) with DLK after LASIK among 148 patients (296 eyes) from December 2007 to May 2008 were selected as control group. Each stage's complex,clinical features and treatment process of DLK were analyzed. Results The incidence rate of DLK in obser-vation group was 4.27%,among which,stage Ⅰ was 3.01%,stage Ⅱ was 0.5% and stage Ⅳ (3 eyes) was 0.75%. The incidence rate of DLK in control group was 2.36%,among which,stage Ⅰ was 1.68% and stage Ⅱ was 0.67%. DLK of stage Ⅰ and stage Ⅱ happened 1～3 days after LASIK,it absorbed entirely after 7～10 days'treatment, and vision rocovered to normal. DLK of stage Ⅳ happened 3～7 days after LASIK, relatively white dense opacity under the lamellar of central cornea and flap melt could be seen through slit lamp. High hyperme-tropia was left after healing. Hypermetropia decreased partly after 3～6 months, and vision recovered to 0.6～1.0. Conclusion The occurrence of DLK after LASIK is related with multifactors. DLK can be prevented by the strict checks on each link of the operation and cured better if it is treated in time.     

LASIK后弥漫性板层角膜炎的临床分析

Objective To study the causes,clinical features and prevention measures of diffuse lamel-lar keratitis (DLK)after LASIK. Methods Eleven patients ( 17 eyes) with DLK after LASIK among 199 pa-floats (398 eyes) from March 2007 to December 2007 were selected as observation group,and after the strict checks on operating room environment,pressure sterilizer,surgical instrument disinfection,preoperative con-junctival sac clean and corneal epithelium protection,5 patients (7 eyes) with DLK after LASIK among 148 patients (296 eyes) from December 2007 to May 2008 were selected as control group. Each stage's complex,clinical features and treatment process of DLK were analyzed. Results The incidence rate of DLK in obser-vation group was 4.27%,among which,stage Ⅰ was 3.01%,stage Ⅱ was 0.5% and stage Ⅳ (3 eyes) was 0.75%. The incidence rate of DLK in control group was 2.36%,among which,stage Ⅰ was 1.68% and stage Ⅱ was 0.67%. DLK of stage Ⅰ and stage Ⅱ happened 1～3 days after LASIK,it absorbed entirely after 7～10 days'treatment, and vision rocovered to normal. DLK of stage Ⅳ happened 3～7 days after LASIK, relatively white dense opacity under the lamellar of central cornea and flap melt could be seen through slit lamp. High hyperme-tropia was left after healing. Hypermetropia decreased partly after 3～6 months, and vision recovered to 0.6～1.0. Conclusion The occurrence of DLK after LASIK is related with multifactors. DLK can be prevented by the strict checks on each link of the operation and cured better if it is treated in time.     

预防术后组织粘连导致限制性斜视的研究进展

外眼手术后局部组织粘连导致限制性眼球运动障碍,患者出现斜视、复视等术后并发症是广大眼科医生所极力避免的。各国学者就此采用异体材料进行多方尝试,主要分为物理屏障和抑制成纤维细胞增殖两方面,取得了一定效果。就如何预防术后外跟组织粘连进行的大量动物及临床实验研究进行综述。     

降酶灵胶囊对急性肝损伤的药效研究

目的观察降酶灵胶囊保肝降酶的作用。方法采用四氯化碳(CCl4)制作小鼠的急性肝损伤模型,然后给予不同剂量降酶灵胶囊,观察小鼠血清谷丙转氨酶(ALT)和肝病理学的变化;用D-氨基半乳糖对大鼠造成急性肝损伤模型,再给予不同剂量降酶灵胶囊,观察大鼠血清ALT和总胆红素(TBIL)的变化。结果降酶灵胶囊0.135、0.270、0.540g/kg组均能明显降低由CCl4引起的小鼠急性肝损伤的ALT;降酶灵胶囊0.135、0.270g/kg组均能显著降低由D-氨基半乳糖所致大鼠急性肝损伤血清ALT与TBIL。结论降酶灵胶囊具有保肝降酶和降低胆红素的作用。